Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447 , November 2008

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

  • William J. Sandborn

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: William J. Sandborn, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. fax: (507) 266-0335

References 

  1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–1640
  2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657
  3. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699–706
  4. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244–250
  5. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956–963
  6. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11
  7. Hoie O, Wolters FL, Riis L, et al. European Collaborative Study Group of Inflammatory Bowel D Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515
  8. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–239
  9. Hueting WE, Buskens E, van der Tweel I, et al. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Digestive Surgery. 2005;22:69–79
  10. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55:1575–1580
  11. Hanauer SB, Sandborn W The Practice Parameters Committee of the American College of G. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635–643
  12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (Crohn's Disease cA2 Study Group). N Engl J Med. 1997;337:1029–1035
  13. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549
  14. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398–1405
  15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. N Engl J Med. 2004;350:876–885
  16. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology. 2006;130:323–333
  17. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838
  18. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. [see comment] Gut. 2007;56:1232–1239
  19. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:56–65
  20. Schreiber S, Rutgeerts P, Fedorak RN, et al. CCsDSG A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807–818
  21. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228–238
  22. Schreiber s, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol maintenance therapy for Crohn's disease. N Engl J Med. 2007;357:239–250
  23. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24–32
  24. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912–1925
  25. Targan SR, Feagan BG, Fedorak RN, et al. Group IEoNiCsDRaRET Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–1683
  26. Faubion WJ, Loftus EJ, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260
  27. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674–678
  28. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660–667
  29. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. [erratum appears in Gut 2005;54:734] Gut. 2005;54:237–241
  30. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of anti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653
  31. Kornbluth A, Sachar DB Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385
  32. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis. 1997;3:65–78
  33. Leung Y, Panaccione R, Hemmelgarn B, et al. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455–1461
  34. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476
  35. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: an analysis from ACT 1 and ACT 2. Am J Gastroenterol. 2007;102(S2):S479–S480[abstract 984]
  36. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease (The North American Crohn's Study Group Investigators). N Engl J Med. 1995;332:292–297
  37. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630
  38. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428–1435
  39. Modigliani R, Mary JY, Simon JF, et al. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Clinical, biological, and endoscopic picture of attacks of Crohn's disease (Evolution on prednisolone). Gastroenterology. 1990;98:811–818
  40. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029–1034
  41. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. [see comment] Gastrointest Endosc. 2006;63:433–442
  42. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. [see comment] Gastroenterology. 2004;126:402–413
  43. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862–869
  44. Feagan BG, Panaccione R, Sandborn WJ, et al. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM. Gastroenterology. 2007;2007:A513
  45. Sands BE, Siegel CA, Spencer M, et al. Natalizumab reduces the hospitalization rate in moderate to severe Crohn's disease patients” a pooled analysis of the ENACT-1 and ENCORE studies. Gastroenterology. 2008;134(Suppl 1):A154
  46. Ardizzone S, Maconi G, Russo A, et al. Randomised, controlled trial, of azathioprine and 5- aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut. 2006;55:47–53
  47. Truelove SC, Witts LJ. Cortisone in ulcerative colitis (Final report on a therapeutic trial). BMJ. 1955;2:1041–1048
  48. Rutgeerts P, Colombel JF, Reinisch W, et al. Infliximab induces and maintains mucosal healing in patients with active ulcerative colitis: the ACT trial experience. Gut. 2005;54(Suppl VII):A58
  49. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895–902
  50. Sandborn W, Rutgeerts P, Reinisch W, Kornbluth A, Lichtiger S, D'Haens G, et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. American Journal of Gastroenterology. 2008;103(S1):S436;[Abstract 1117]
  51. PRNewswire. New findings shor efficacy of Remicade compared with azathioprine in treatment of Crohn's disease according to first-of-its-kind study. [Press release], October 6, 2008 http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-06-2008/0004898242&EDATE=Accessed October 6, 2008
  52. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology. 2007;132:A147
  53. Sandborn WJ, Colombel JF, Panes J, et al. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease: data from PRECiSE 2. Am J Gastroenterol. 2006;101:S454–S455(Abstract 1109)
  54. Cosnes J, de Parades V, Carbonnel F, et al. Classification of the sequelae of bowel resection for Crohn's disease. Br J Surg. 1994;81:1627–1631
  55. Toruner M, Loftus EV, Colombel JF, et al. Risk factors for opportunistic infections in inflammatory bowel diseases: a case-control study. Gastroenterology. 2008;134:929–936
  56. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. [see comment] Gut. 2005;54:1121–1125
  57. Beaugerie L, Carrat F, Bouvier AM, et al. Excess risk of lymphoproliferative disorders (Lpd) in inflammatory bowel diseases (IBD): interim results of the Cesame cohort. Gastroenterology. 2008;134(Suppl 1):A116–A117
  58. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–267
  59. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. [see comment] Gastroenterology. 2006;130:650–656
  60. Dubinsky MC, Lin YC, Dutridge D, et al. Western Regional Pediatric IBDRA Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–367
  61. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542–553
  62. Lichtenstein GR, Diamond RH, Wagner C, et al. Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators. Gastroenterology. 2007;132(Suppl 2):A146
  63. Feagan BG. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD). Gastroenterology (in press).
  64. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–1868
  65. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459
  66. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–1353
  67. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. [see comment] Clin Gastroenterol Hepatol. 2005;3:1015–1021
  68. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Infliximab treatment for ulcerative colitis: comparable clinical response, clinical remission, and mucosal healing in patients with disease duration < 3 years vs >= 3 years. Gastroenterology. 2008;134(Suppl 1):A495

 The author discloses the following: Dr Sandborn is supported by Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma. Dr Sandborn is a consultant for Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Salix Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma, and Elan.

PII: S0016-5085(08)01784-8

doi: 10.1053/j.gastro.2008.09.053

Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447 , November 2008

Article Tools

* Image Usage & Resolution